NovaBay Pharmaceuticals Inc Total Liabilities
NovaBay Pharmaceuticals Inc total liabilities. Based on the latest financial reports, NovaBay Pharmaceuticals Inc (NBY) has total liabilities worth $31.86 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are NovaBay Pharmaceuticals Inc's assets to evaluate the company's liquid asset resilience ratio.
Total Liabilities of NovaBay Pharmaceuticals Inc (2003–2025)
Total liabilities of NovaBay Pharmaceuticals Inc from 2003 to 2025. This chart illustrates how NovaBay Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data.
NovaBay Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of NovaBay Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Akme Fintrade India Ltd
NSE:AFIL
|
India | Rs5.10 Billion |
|
Tera Software Limited
NSE:TERASOFT
|
India | Rs1.56 Billion |
|
Omni-Lite Industries Canada Inc.
V:OML
|
Canada | CA$6.80 Million |
|
Clean TEQ Water Ltd
AU:CNQ
|
Australia | AU$7.72 Million |
|
Edip Gayrimenkul Yatirim Sanayi ve Ticaret AS
IS:EDIP
|
Turkey | TL1.37 Billion |
|
Singtex Industrial Co Ltd
TWO:4433
|
Taiwan | NT$4.56 Billion |
|
Bowim S.A.
WAR:BOW
|
Poland | zł286.49 Million |
|
Cnova NV
PA:CNV
|
France | €1.28 Billion |
Liability Composition Analysis (2003–2025)
This chart breaks down NovaBay Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see NBY total asset value.
Liquidity & Leverage Metrics
NovaBay Pharmaceuticals Inc Total Liabilities Ratios Explained
NovaBay Pharmaceuticals Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.60 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.40 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 3.53 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how NovaBay Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for NovaBay Pharmaceuticals Inc (2003–2025)
The table below shows the annual total liabilities of NovaBay Pharmaceuticals Inc from 2003 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $31.86 Million | +796.99% |
| 2024-12-31 | $3.55 Million | -37.90% |
| 2023-12-31 | $5.72 Million | -2.14% |
| 2022-12-31 | $5.84 Million | -57.67% |
| 2021-12-31 | $13.81 Million | +372.84% |
| 2020-12-31 | $2.92 Million | -71.50% |
| 2019-12-31 | $10.25 Million | +132.52% |
| 2018-12-31 | $4.41 Million | -41.12% |
| 2017-12-31 | $7.49 Million | -9.60% |
| 2016-12-31 | $8.28 Million | -18.62% |
| 2015-12-31 | $10.18 Million | +78.85% |
| 2014-12-31 | $5.69 Million | -20.26% |
| 2013-12-31 | $7.13 Million | +37.56% |
| 2012-12-31 | $5.19 Million | -21.65% |
| 2011-12-31 | $6.62 Million | +31.70% |
| 2010-12-31 | $5.03 Million | +20.30% |
| 2009-12-31 | $4.18 Million | -36.93% |
| 2008-12-31 | $6.62 Million | -31.01% |
| 2007-12-31 | $9.60 Million | -4.49% |
| 2006-12-31 | $10.05 Million | +3142.90% |
| 2005-12-31 | $310.00K | -39.57% |
| 2003-12-31 | $513.00K | -- |
About NovaBay Pharmaceuticals Inc
NovaBay Pharmaceuticals, Inc. engages in the accumulation and holding of digital assets for participation in blockchain-based networks. The company focuses on the accumulation, holding, and deployment of SKY, a protocol token of the decentralized Sky Protocol. Its services intend to support protocol-level services, including staking, governance participation, validation, and related activities. T… Read more